Recent developments include quarterly earnings reports with revenue and earnings exceeding expectations, significant stock price appreciation over the past year, and ongoing strategic divestitures.

• Neogen reported Q4 2026 earnings and revenue exceeding expectations [N1].
• The company's stock gained 101.1% over the past year, driven by operational performance and market factors [N2].
• Q3 2026 earnings transcript and analysis highlighted revenue growth but noted a decline in gross margin, impacting stock price [N3][N4].
• Q3 2025 and Q3 2026 earnings reports showed revenue and earnings exceeding estimates, with a widened loss and updated revenue outlook for fiscal year 2026 [N5][N7][N8].

Neogen's diversified product lines in food safety and animal health address critical and growing needs for contamination detection, hygiene monitoring, and animal disease prevention. The company's global footprint and strong sales infrastructure support broad market access. Continued innovation through research and development and strategic divestitures, such as the Cleaners and Disinfectants business and the planned sale of the Genomics segment, may allow Neogen to focus resources on core growth areas. Recent positive earnings reports and stock performance gains reflect operational execution and market interest.

Neogen faces risks including regulatory approvals related to its Genomics business divestiture, competitive pressures in diagnostic and animal health markets, and potential fluctuations in demand from its diverse customer base. The company reported a net loss and negative earnings per share in the latest fiscal year, indicating profitability challenges. Changes in royalty costs for licensed technologies and integration risks from acquisitions or divestitures may impact financial performance. Market reactions to earnings volatility, such as gross margin declines, have affected stock price behavior.

Neogen's moat is supported by its proprietary technologies in diagnostic testing, including immunoassay and nucleic acid detection methods, and its broad product portfolio spanning food safety and animal health markets. Its extensive global sales and distribution network, combined with specialized sales and technical support teams, enhances customer reach and service. The company's ongoing investment in research and development and strategic acquisitions contribute to product innovation and market expansion. Additionally, certain products benefit from exclusive or licensed technologies, providing competitive differentiation.

• Regulatory Approval Risk: The sale of the Genomics business to Zoetis is subject to customary closing conditions and regulatory approvals, with ongoing reviews by competition authorities in Australia and New Zealand [S1].
• Profitability Challenges: Neogen reported a net loss of $7.9 million and negative EPS of $0.04 for fiscal year 2026, indicating challenges in achieving consistent profitability [S1].
• Market and Competitive Risks: The company operates in competitive markets for food safety and animal health products, facing risks from competitors and changing customer demands [S1].
• Royalty and Licensing Costs: Neogen incurs royalty expenses for licensed technologies used in its products, which can range from 2% to 10% of revenues and may impact margins [S1].
• Integration and Execution Risks: Divestitures and acquisitions require effective integration and execution to realize strategic benefits and avoid operational disruptions [S1].

• Neogen Corporation develops, manufactures, and markets products and services dedicated to food and animal safety [S1].
• The Food Safety segment includes diagnostic test kits and complementary products sold to food and animal feed producers and processors to prevent contamination and foodborne illnesses, including tests for pathogens, toxins, allergens, and hygiene monitoring [S1].
• Food Safety products include natural toxins and allergen detection, bacterial and sanitation testing, molecular detection systems, culture media, and food safety data software [S1].
• The Animal Safety segment offers veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent and insect control products, and genomics testing services [S1].
• Animal Safety products are marketed through veterinarians, retailers, livestock producers, and distributors worldwide [S1].
• Neogen divested its global Cleaners and Disinfectants business in July 2025 [S1].
• Neogen announced an agreement to sell its Genomics business to Zoetis Inc. for $160 million, with regulatory reviews ongoing as of mid-2026 [S1].
• The company has a global sales presence with offices in 28 countries and a network of distributors in over 100 countries [S1].
• Sales to customers outside the U.S. accounted for approximately 51.2% of total revenues for fiscal year ended May 31, 2026 [S1].
• Neogen employs 817 sales and marketing personnel and 89 research and development staff as of May 31, 2026 [S1].
• Research and development focuses on innovative new products and enhancements, with expenditures approximating 2% to 5% of total revenues annually [S1].
• Financial snapshot as of May 31, 2026: cash and equivalents of $185.5 million, current assets of $604.6 million, current liabilities of $158.2 million, current ratio of 3.82, cash ratio of 1.17, net loss of $7.9 million, and basic and diluted EPS of -$0.04 [S1].
• Recent news highlights include Q4 2026 earnings and revenue exceeding expectations, a 101.1% gain in stock price over the past year, and ongoing earnings call transcripts and analyses [N1][N2][N3][N4][N5][N7][N8].